Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013-07-01
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
Abstract
Purpose
To determine whether there is a benefit to adjuvant radiation therapy after breast-conserving surgery and tamoxifen in women age ≥ 70 years with early-stage breast cancer.
Patients and methods
Between July 1994 and February 1999, 636 women (age ≥ 70 years) who had clinical stage I (T1N0M0 according to TNM classification) estrogen receptor (ER) -positive breast carcinoma treated by lumpectomy were randomly assigned to receive tamoxifen plus radiation therapy (TamRT; 317 women) or tamoxifen alone (Tam; 319 women). Primary end points were time to local or regional recurrence, frequency of mastectomy, breast cancer-specific survival, time to distant metastasis, and overall survival (OS).
Results
Median follow-up for treated patients is now 12.6 years. At 10 years, 98% of patients receiving TamRT (95% CI, 96% to 99%) compared with 90% of those receiving Tam (95% CI, 85% to 93%) were free from local and regional recurrences. There were no significant differences in time to mastectomy, time to distant metastasis, breast cancer-specific survival, or OS between the two groups. Ten-year OS was 67% (95% CI, 62% to 72%) and 66% (95% CI, 61% to 71%) in the TamRT and Tam groups, respectively.
Conclusion
With long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains. However, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation. Depending on the value placed on local recurrence, Tam remains a reasonable option for women age ≥ 70 years with ER-positive early-stage breast cancer.
Related Questions
Should we be performing sentinel lymph node biopsies for HR+ patients ≥70 years of age?
I do not think that the monarchE data for adjuvant abemaciclib warrants changing our standard practice around omission of SLNB for patients >/= 70 yo with low-risk HR+/HER2- tumors that are clinically node-negative, because adjuvant abemaciclib is largely only appropriate for higher risk tumors and ...
How do you approach axillary radiation in a patient with breast cancer who did not have a sentinel node biopsy?
Choose wisely. The message from the surgery group discourages SNLN bx in 70 and above with low to intermediate grade pathology. As far as RT is concerned, AI alone, APBI, and 5 fraction whole breast are all reasonable options in those patients, and not having SNLN would not change recommendations. T...
What early stage breast cancer patients would you give IOeRT?
I think given data from ELIOT update (11% LR with electron IORT vs. 2% WBI) and the TARGIT-A update, there is a limited role for IORT as monotherapy at this time, particularly when options like 5 fx PBI and 5 fx WBI are now possible. The ABS guidelines do not recommend either IORT technique which is...
Would a finding of isolated tumor cells on SNB impact your decision to offer omission of radiation in a patient with breast cancer who is otherwise a candidate?
ITCs raise our eyebrows, for sure, but are not technically a reason to treat. As this was not recorded in the CALGB study and the majority of patients did not have any axillary evaluation, it is quite likely a portion of patients had ITCs, and yet still did not have excessive rates of recurrence.Tha...
For patients with DCIS on biopsy but invasive disease in lumpectomy, are there any circumstances in which you would not recommend returning for a SNB?
As in all invasive breast cancer, SLNBx is standard unless it will not affect management - and this is usually for the determination of systemic therapy, i.e., chemotx. Such as a patient whose comorbidities preclude chemo for pSLN+, or patients who meet the criteria for good outcomes without knowing...
Are there any special radiotherapy considerations for women who have double lumpectomy?
Z11102 looked at multiple ipsilateral breast cancers and lumpectomies. For these cases, I would be fine with hypofractionated WBI. Boost would be based on features of each cancer so if it was otherwise low risk for both, I would omit boost vs. if both were higher risk (< 50, ER-), I would boost both...
Does the presence of DCIS in conjunction with invasive breast cancer require consideration of adjuvant RT where invasive disease alone may allow for omission?
I'm not sure there is a lot of data in the PRIME II/CALGB 9343 subset of patients looking at impact of associated DCIS in conjunction with invasive disease and its impact on recurrence with and without radiation therapy. I have not considered this an additional risk factor and have offered omission ...
Do you consider omitting adjuvant radiation therapy in an older patient with node positive TNBC who achieve pCR to neoadjuvant chemotherapy?
It depends on what surgery the patient has received. If lumpectomy plus SLNB, I would not omit unless there is absolute contraindications, intolerance to radiation therapy. PRIME II, CALGB 9343, and this meta-analysis provided evidence that post lumpectomy radiation therapy can be omitted in women >...
Do you skip sentinel lymph node biopsy for women >70 years old with small (< 2cm) HR+ node-negative breast cancer?
I often omit sentinel lymph node biopsy in women >70 years of age with T1 breast cancers. As mentioned in the question, this is based on the Choosing Wisely guidelines available on the Society of Surgical Oncology website. I was actually part of the group that developed this recommendation and suppo...
Are there situations in which you would definitely recommend radiation in an elderly patient with ER+, early stage breast cancer?
I always have a little trepidation in answering questions whereby I would “definitely†recommend any therapeutic path as clinical decision making needs to be a bit more nuanced. Every situation requires a careful weighing of multiple inputs including clinical trial data and patient-specific fact...
For an early stage, estrogen receptor positive breast cancer in an elderly patient, would you recommend: hormonal therapy alone, radiation alone or both?
Based on the CALGB (and PRIME II, shorter follow up) data hormonal therapy without RT is a reasonable choice for many older patients given that there is no survival advantage to the addition of RT. Some patients who are in excellent health and want the maximum risk reduction, may be candidates for a...
Would you recommend post lumpectomy RT in an elderly woman with a T1N0M0 stage breast cancer ER/PR/HER2 positive?
As your question states, neither CALGB 9343 nor the PRIME II study assessed HER2 status of its patients as both of these trials commenced prior to the routine testing of HER2 status. So we cannot glean any information from these randomized trials of the omission of radiation in the ER+ HER2+ patient...
Would you consider adjuvant RT in an elderly patient with a T1N0 ER+ breast cancer who initially proceeds with endocrine therapy alone and is unable to tolerate it?
Given the low-risk nature of T1N0 luminal lesions among older patients (per the CALGB 9343 and Prime II trials), the conundrum of whether to pursue adjuvant endocrine therapy, radiotherapy (RT), or both after lumpectomy arises with some frequency. Patients who decline RT yet ultimately cannot tolera...
How long do you give adjuvant hormonal therapy for women over 70 with breast cancer treated with lumpectomy only?
It is always difficult to make a recommendation for endocrine therapy duration when optimal duration is unknown. Looking at CALGB 9343 (Hughes et al, JCO 2013), in which women with stage I cancers were randomly assigned to either tamoxifen plus radiation or tamoxifen alone, we know that the risk of ...
What is the best management of early stage breast cancer in patients with a minimal life expectancy (<10yrs)?
I believe in individualized, whole patient care. Life expectancy is incredibly difficult to estimate, but if we are somehow certain a patient will live less than 10 years, then quality (rather than quantity) of life likely becomes the primary concern of a patient with early stage breast cancer. We d...
What is the age cut-off to omit radiation therapy after breast conserving surgery for early stage breast cancer?
I agree with the above answers and would like to expand a bit. What is so special about being over 70 (or over 65 for that matter) when your breast cancer is diagnosed? Not much. Age is a rough surrogate for life expentancy and perhaps also for biologic subtype. But we have SEVERAL trials across bro...
Does current data support use of intraoperative breast radiotherapy?
I use the intrabeam IORT system and have treated about 90 patients. 22% have been given adjuvant whole breast or breast/axilla/scf xrt. The toxicity of IORT is significantly lower than other forms of APBI and external beam. The results of the Targit A trial support our experience in regards to toxic...